The correlation of tumor site, KRAS mutation and mismatch repair (MMR) status on the survival outcome of colorectal carcinoma patient with conventional chemotherapy: a systematic review

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, and survival outcomes are influenced by tumor sidedness, KRAS mutation status, and mismatch repair (MMR) status. This systematic review evaluated the correlations between these factors and survival outcomes. We performed a comprehensive search of the PubMed, Cochrane Library, and Scopus databases identified studies on adult CRC patients by tumor sidedness, KRAS mutation status, and MMR status. Observational and interventional studies reporting the DFs, PFS, and OS were included. Twenty-eight studies (N = 169,582 patients) met the eligibility criteria. Right-sided tumors were generally associated with poorer overall survival (OS) and disease-free survival (DFS) compared to the left-sided tumors in several studies. KRAS mutation status consistently emerged as a prognostic biomarker influencing treatment response and survival outcomes in CRC patients. Study heterogeneity and complete molecular data are the limitations of this study. Tumor sidedness, KRAS mutations, and MMR status significantly influenced CRC survival outcomes. The findings of this systematic review emphasize the importance of molecular profiling and tumor characteristics in treatment decisions.